Kininogen in autoimmune uveitis: Decrease in peripheral blood stream versus increase in target tissue

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 1, 2010, Pages 375-382

  Zipplies, Johanna K ^a   Hauck, Stefanie M ^b   Schoeffmann, Stephanie ^b   Amann, Barbara ^a   van der Meijden, Christiaan H ^a   Stangassinger, Manfred ^a   Ueffing, Marius ^b   Deeg, Cornelia A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN A4; BETA2 GLYCOPROTEIN 1; FETUIN A; HIGH MOLECULAR WEIGHT KININOGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN G5; IMMUNOGLOBULIN M; PLASMA PROTEIN; PROTEOME; TRANSFERRIN; UNCLASSIFIED DRUG; VASCULOTROPIN; AUTOANTIGEN; KININOGEN; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; EQUINE RECURRENT UVEITIS; EYE INFLAMMATION; HORSE; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; RETINA; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; UVEITIS; VITREOUS BODY; WESTERN BLOTTING; ANIMAL; ANIMAL DISEASE; BLOOD; FLUORESCENT ANTIBODY TECHNIQUE; HORSE DISEASE; MASS SPECTROMETRY; METABOLISM; RECURRENT DISEASE;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; BLOOD PROTEINS; BLOTTING, WESTERN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HORSE DISEASES; HORSES; KININOGEN, HIGH-MOLECULAR-WEIGHT; KININOGENS; RECURRENCE; RETINA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; UP-REGULATION; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 75749151760     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4094     Document Type: Article

References (50)

1. Spiess BM. Equine recurrent uveitis (in German). Schweiz Arch Tierheilkd. 1997;139:126-133.
2. Cook PRL, Harling DE. Equine recurrent uveitis. Equine Vet J Suppl. 1983;15:57-60.
3. Deeg CA, Ehrenhofer M, Thurau SR, Reese S, Wildner G, Kaspers B. Immunopathology of recurrent uveitis in spontaneously diseased horses. Exp Eye Res. 2002;75:127-133.
4. Deeg CA, Hauck SM, Amann B, et al. Equine recurrent uveitis: a spontaneous horse model of uveitis. Ophthalmic Res. 2008;40:151-153.
5. Mochizuki M, Kuwabara T, McAllister C, Nussenblatt RB, Gery I. Adoptive transfer of experimental autoimmune uveoretinitis in rats: immunopathogenic mechanisms and histologic features. Invest Ophthalmol Vis Sci. 1985;26:1-9.
6. Deeg CA, Pompetzki D, Raith AJ, et al. Identification and functional validation of novel autoantigens in equine uveitis. Mol Cell Proteomics. 2006;5:1462-1470.
7. Deeg CA, Reese S, Gerhards H, Wildner G, Kaspers B. The uveitogenic potential of retinal S-antigen in horses. Invest Ophthalmol Vis Sci. 2004;45:2286-2292.
8. Deeg CA, Thurau SR, Gerhards H, Ehrenhofer M, Wildner G, Kaspers B. Uveitis in horses induced by interphotoreceptor retinoid-binding protein is similar to the spontaneous disease. Eur J Immunol. 2002;32:2598-2606.
9. Issaq HJ, Veenstra TD. The role of electrophoresis in disease biomarker discovery. Electrophoresis. 2007;28:1980-1988.
10. Deeg CA, Altmann F, Hauck SM, et al. Down-regulation of pigment epithelium-derived factor in uveitic lesion associates with focal vascular endothelial growth factor expression and breakdown of the blood-retinal barrier. Proteomics. 2007;7:1540-1548.
11. Hauck SM, Schoeffmann S, Amann B, et al. Retinal Mueller glial cells trigger the hallmark inflammatory process in autoimmune uveitis. J Proteome Res. 2007;6:2121-2131.
12. Pieper R, Gatlin CL, Makusky AJ, et al. The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics. 2003;3:1345-1364.
13. Zipplies JK, Hauck SM, Schoeffmann S, et al. Serum PEDF levels are decreased in a spontaneous animal model for human autoimmune uveitis. J Proteome Res. 2009;8:992-998.
14. Bischoff R, Luider TM. Methodological advances in the discovery of protein and peptide disease markers. J Chromatogr B. 2004;803:27-40.
15. Issaq HJ, Xiao Z, Veenstra TD. Serum and plasma proteomics. Chem Rev. 2007;107:3601-3620.
16. Deeg CA, Kaspers B, Gerhards H, Thurau SR, Wollanke B, Wildner G. Immune responses to retinal autoantigens and peptides in equine recurrent uveitis. Invest Ophthalmol Vis Sci. 2001;42:393-398.
17. Liu T, Qian WJ, Mottaz HM, et al. Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. Mol Cell Proteomics. 2006;5:2167-2174.
18. Lilley KS, Friedman DB. All about DIGE: quantification technology for differential-display 2-D-gel proteomics. Expert Rev Proteomics. 2004;1:401-409.
19. Fodor IK, Nelson DO, Alegria-Hartman M, et al. Statistical challenges in the analysis of two-dimensional difference gel electrophoresis experiments using DeCyder. Bioinformatics. 2005;21:3733-3740.
20. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845-867.
21. Hinerfeld D, Innamorati D, Pirro J, Tam SW. Serum/Plasma depletion with chicken immunoglobulin Y antibodies for proteomic analysis from multiple Mammalian species. J Biomol Tech. 2004;15:184-190.
22. Wagner B, Miller DC, Lear TL, Antczak DF. The complete map of the Ig heavy chain constant gene region reveals evidence for seven IgG isotypes and for IgD in the horse. J Immunol. 2004;173:3230-3242.
23. Estes DM, Brown WC. Type 1 and type 2 responses in regulation of Ig isotype expression in cattle. Vet Immunol Immunopathol. 2002;90:1-10.
24. Snapper CM, Marcu KB, Zelazowski P. The immunoglobulin class switch: beyond "accessibility". Immunity. 1997;6:217-223.
25. Staudt A, Dorr M, Staudt Y, et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J. 2005;150:729-736.
26. Wong A, Kenny TP, Ermel R, Robbins DL. IgG3 reactive rheumatoid factor in rheumatoid arthritis: etiologic and pathogenic considerations. Autoimmunity. 1994;19:199-210.
27. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A. 2000;97:1184-1189.
28. Deeg CA, Amann B, Raith AJ, Kaspers B. Inter-and intramolecular epitope spreading in equine recurrent uveitis. Invest Ophthalmol Vis Sci. 2006;47:652-656.
29. Macedo MF, de Sousa M, Ned RM, Mascarenhas C, Andrews NC, Correia-Neves M. Transferrin is required for early T-cell differentiation. Immunology. 2004;112:543-549.
30. Caspi RR, Roberge FG, McAllister CG, et al. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol. 1986;136:928-933.
31. Kim SJ, Kim S, Park J, et al. Differential expression of vitreous proteins in proliferative diabetic retinopathy. Curr Eye Res. 2006;31:231-240.
32. Sato H, Kazama JJ, Wada Y, et al. Decreased levels of circulating alpha2-Heremans-Schmid glycoprotein/Fetuin-A (AHSG) in patients with rheumatoid arthritis. Intern Med. 2007;46:1685-1691.
33. Wang H, Zhang M, Bianchi M, Sherry B, Sama A, Tracey KJ. Fetuin (alpha2-HS-glycoprotein) opsonizes cationic macrophage deactivating molecules. Proc Natl Acad Sci U S A. 1998;95:14429-14434.
34. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol. 2004;5:981-986.
35. Walport MJ. Complement: first of two parts. N Engl J Med. 2001;344:1058-1066.
36. Bora NS, Jha P, Bora PS. The role of complement in ocular pathology. Semin Immunopathol. 2008;30(2):85-95.
37. Jha P, Sohn JH, Xu Q, et al. The complement system plays a critical role in the development of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci. 2006;47:1030-1038.
38. Sainz IM, Pixley RA, Colman RW. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost. 2007;98:77-83.
39. Guo YL, Colman RW. Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. J Thromb Haemost. 2005;3:670-676.
40. Guo YL, Wang S, Colman RW. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler Thromb Vasc Biol. 2001;21:1427-1433.
41. Guo YL, Wang S, Colman RW. Kininostatin as an antiangiogenic inhibitor: what we know and what we do not know. Int Immunopharmacol. 2002;2:1931-1940.
42. Clements J, Mukhtar A, Yan S, Holland A. Kallikreins and kinins in inflammatory-like events in the reproductive tract. Pharmacol Res. 1997;35:537-540.
43. Sainz IM, Isordia-Salas I, Castaneda JL, et al. Modulation of inflammation by kininogen deficiency in a rat model of inflammatory arthritis. Arthritis Rheum. 2005;52:2549-2552.
44. Isordia-Salas I, Pixley RA, Li F, et al. Kininogen deficiency modulates chronic intestinal inflammation in genetically susceptible rats. Am J Physiol Gastrointest Liver Physiol. 2002;283:G180-G186.
45. Barbasz A, Guevara-Lora I, Rapala-Kozik M, Kozik A. Kininogen binding to the surfaces of macrophages. Int Immunopharmacol. 2008;8:211-216.
46. DiScipio RG. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology. 1982;45:587-595.
47. Hiemstra PS, Daha MR, Bouma BN. Activation of factor B of the complement system by kallikrein and its light chain. Thromb Res. 1985;38:491-503.
48. Colman RW, Pixley RA, Sainz IM, et al. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecularweight kininogen. J Thromb Haemost. 2003;1:164-170.
49. Hayashi I, Amano H, Yoshida S, et al. Suppressed angiogenesis in kininogen-deficiencies. Lab Invest. 2002;82:871-880.
50. Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell SE, Feener EP. Plasma kallikrein mediates angiotensin II type 1 receptorstimulated retinal vascular permeability. Hypertension. 2009;53:175-181.